RETICULOCYTE HEMOGLOBIN CONTENT AN IMPORTANT PARAMETER WHICH INCREASES THE EFFICACY OF ANEMIA MANAGEMENT IN HEMODIALYSIS PATIENTS
|Full paper||Not Available|
Anemia is a leading symptom of CRF' and is present in over 9096 of the dialyzed patients. Introduction of recombinant human erythropoietirt (rHuEPo) into routine therapy of uraemic anemia has dramatically reduced or even eliminated the need of blood transfusion and improved the quality of life . All CKD patients with renal anemia undergoing treatment with rHuEPO should be given supplementary iron to maintain or reach the Hb targets. Regardless of dialysis status Iron deficiency is the most important cause of a suboptimal response to rHuEpo therapy ,determing the proper dose is a chnilrnge topic. * This work has been carried out to evaluate efficacy of Reticvlolyte Hemoglobin Content (CHr) in management of anemia in CRY under dialysis. Our study included 50 patients with ESRD on hernodialysis divided into 2 groups, (A) include 25 patient with E.S.R.D where Anemia management depend on Transfenin Saturation (MAT%) and serum ferittin and group (B) with ESRD where anemia management depend on CHr and serg umferittin In our study we found that: * There was no significant difference between group A and B as regard CRP(11.8±5.5 and 9.7+3.9 p>0.05 ) and also no dyference in Hb96 at the start and end of study of both groups(8.9+I .9 - 7.6±I.7 p>0,05 andl 0.6+2.9- 10. 1+2.8 respectively) * There was significance difference between the two group as regarding doses of IX iron (mg) and doses of rHuEPo (units).